Co-occurrence of rearrangements of MYC and BCL2 and/or BCL6 translocations was reported in 2–8% of all DLBCL including patients from clinical trials and a population-based registries [40•, 46]. Here, BCL2 is linked to diffuse large B-cell lymphoma.